Ethics Committee of Shanghai Renji Hospital
Ethics Committee of Shanghai Renji Hospital
Shanghai, Shanghai Municipality, China2 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Biomarker-Enriched Kidney-Preserving Strategy With Disitamab Vedotin Plus Tislelizumab in HER2-Positive High-Risk Upper Tract Urothelial Carcinoma | renal pelvis/ureter urothelial carcinoma | Not yet recruiting | Phase 2 | 2026-05-13 | NCT07584733 | |
| Combination of DV and Tislelizumab for Renal Preservation in High-risk UTUC Patients | HER-2 ADC; Kidney Preservation; PD-1antibody; Upper Urinary Tract Urothelial Carcinoma | Recruiting | Phase 2 | 2025-12-09 | NCT05912816 |